Josef von Rickenbach Net Worth

The estimated Net Worth of Rickenbach Josef H Von is at least $1.28 Миллион dollars as of 8 June 2020. Mr. Von owns over 227,272 units of Aileron Therapeutics Inc stock worth over $1,282,925 and over the last 8 years he sold ALRN stock worth over $0. In addition, he makes $0 as Independent Director at Aileron Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rickenbach ALRN stock SEC Form 4 insiders trading

Josef has made over 7 trades of the Aileron Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 227,272 units of ALRN stock worth $249,999 on 8 June 2020.

The largest trade he's ever made was buying 227,272 units of Aileron Therapeutics Inc stock on 8 June 2020 worth over $249,999. On average, Josef trades about 21,807 units every 53 days since 2016. As of 8 June 2020 he still owns at least 445,460 units of Aileron Therapeutics Inc stock.

You can see the complete history of Mr. Von stock trades at the bottom of the page.

Josef von Rickenbach biography

Josef H. von Rickenbach serves as Independent Director of the Company. Mr. von Rickenbach is currently the managing director of Stet Vision LLC. He co-founded and served as President and Chief Executive Officer of HelioVision, Inc., a biotechnology company, from April 2017 until its acquisition by Aldeyra Therapeutics, Inc. in February 2019. Previously, Mr. von Rickenbach founded Parexel International Corporation (“Parexel”), in 1982 and served as a director, Chairman of the Board and Chief Executive Officer of Parexel from 1983 until Parexel’s acquisition by Pamplona Capital Management, LLP in September 2017. He also served as President of Parexel from 1983 to April 2001 and from July 2005 to July 2012. Mr. von Rickenbach received an M.B.A. from Harvard Business School and a B.A. in Business Economics from the Lucerne University of Applied Sciences and Arts in Switzerland.

How old is Josef Rickenbach?

Josef Rickenbach is 65, he's been the Independent Director of Aileron Therapeutics Inc since 2019. There are 1 older and 11 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.

What's Josef Rickenbach's mailing address?

Rickenbach's mailing address filed with the SEC is 195 West St, Waltham, MA 02451, USA.

Insiders trading at Aileron Therapeutics Inc

Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag... и Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.

What does Aileron Therapeutics Inc do?

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig

Complete history of Mr. Von stock trades at Aileron Therapeutics Inc

Aileron Therapeutics Inc executives and stock owners

Aileron Therapeutics Inc executives and other stock owners filed with the SEC include:

• Manuel Aivado,
  President, Chief Executive Officer, Director
• Dr. Manuel C. Aivado,
  Pres, CEO & Director
• Dr. Vojislav Vukovic M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Vojislav Vukovic,
  Senior Vice President, Chief Medical Officer
• Richard J. Wanstall M.B.A.,
  SVP, CFO & Treasurer
• D. Allen Annis,
  Senior Vice President - Research
• Jeffrey Bailey,
  Chairman of the Board
• Rick Wanstall,
  Chief Financial Officer, Treasurer
• Jodie Morrison,
  Independent Director
• Reinhard Ambros,
  Lead Independent Director
• Josef von Rickenbach,
  Independent Director
• Nolan Sigal,
  Independent Director
• William McKee,
  Independent Director
• Dr. D. Allen Annis Ph.D.,
  Sr. VP of Research
• Alan A Musso,
  
• Allen Annis,
  SVP, Research
• 2008 Trust The Edward & Mic...,
  10% owner
• Edward M Elkin,
  Director
• Gary J Knauer,
  CFO, Treasurer & Secretary
• Glenda Baskin Glover,
  Director
• Joseph Looney,
  Director
• Peter Gutmann,
  Director
• Gary Gelman,
  Chairman, President & CEO
• Kira Nelson,
  See Remarks
• Donald Dougherty,
  SVP & Chief Financial Officer
• Caleb Maxfield Winder,
  Director
• Tree Partners Ii Annex, L...,
  10% owner
• Ib Investment Co., Ltd. Aju,
  10% owner
• Medical Fund Lp Gullans Ste...,
  
• Ltd. Kck,
  10% owner
• Llc Cvf,,
  10% owner
• John H Mcarthur,
  Director
• Joseph A., Iii Yanchik,
  See Remarks
• Armen Shanafelt,
  Director
• Brian M. Jr. Gallagher,
  Director
• Tree Partners Ii Lp Apple,
  10% owner
• Management Group, Llc Lilly...,
  
• Emerging Markets Ltd. Sigma,
  10% owner
• Jon B. Platt,
  10% owner
• Scott Kapnick,
  Director
• Bioventures Ltd Novartis Ag...,
  
• Kathryn Gregory,
  SVP, Chief Business Officer
• John P Phd Longenecker,
  President and CEO
• Muneer A Satter,
  See Remarks
• Vojo Vukovic,
  Chief Medical Officer
• William Fairey,
  
• James Brian Windsor,
  President and COO
• Of Texas/Texas Am Investmen...,
  10% owner